Physiologically based pharmacokinetic modeling and simulation in pediatric drug development

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 11, 2014, Pages

  Maharaj, A R ^a   Edginton, A N ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DOSE; DRUG ELIMINATION; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION;

EID: 84927761587     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.45     Document Type: Article

References (42)

1. Edginton, A.N., Theil, F.P., Schmitt, W. & Willmann, S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 4, 1143-1152 (2008).
2. Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
3. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
4. Huang, S.M., Abernethy, D.R., Wang, Y., Zhao, P. & Zineh, I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 102, 2912-2923 (2013).
5. Poulin, P. et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci.; e-pub ahead of print 3 May 2011.
6. Maharaj, A.R., Barrett, J.S. & Edginton, A.N. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 15, 455-464 (2013).
7. Björkman, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59, 691-704 (2005).
8. Johnson, T.N., Zhou, D., Bui, K.H. Development of physiologically-based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm. Drug Dispos. 35, 341-352 (2014).
9. Khalil, F. & Läer, S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 16, 226-239 (2014).
10. Willmann, S. et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin. Pharmacokinet. 53, 89-102 (2014).
11. Jiang, X.L., Zhao, P., Barrett, J.S., Lesko, L.J. & Schmidt, S. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst. Pharmacol. 2, e80 (2013).
12. Pan, Y., Grillo, J., Hsu, V., Zhang, L., Sinha, V., & Huang, S. Application of the FDA PBPK knowledgebase in evaluating model predictability for drug-drug interactions. Clin. Pharmacol.Ther. 95. 2014.
13. West, G.B., Brown, J.H. & Enquist, B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284, 1677-1679 (1999).
14. Anderson, B.J. & Holford, N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36 (2009).
15. Edginton, A.N., Shah, B., Sevestre, M. & Momper, J.D. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin. Pharmacokinet. 52, 693-703 (2013).
16. Edginton, A.N. & Willmann, S. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paed. Perinat. Drug Ther. 7:146-153 (2006).
17. Tod, M., Jullien, V. & Pons, G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47, 231-243 (2008).
18. Edginton, A.N. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr. Anaesth. 21, 206-213 (2011).
19. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926-931 (2012).
20. Jones, H.M., Mayawala, K. & Poulin, P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 15, 377-387 (2013).
21. Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238-1257 (2006).
22. Yun, Y.E. & Edginton, A.N. Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica. 43, 839-852 (2013).
23. Yun, Y.E., Cotton, C.A. & Edginton, A.N. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. J. Pharmacokinet. Pharmacodyn. 41, 1-14 (2014).
24. Rostami-Hodjegan, A. & Tucker, G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148 (2007).
25. Edginton, A.N., Schmitt, W. & Willmann, S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034 (2006).
26. World Health Organization. International Programme on Chemical Safety Harmonization Project. Characterization and application of physiologically based pharmacokinetic models in risk assessment. Harmonization Project Document No. 9. online. http://www.who.int/ipcs/methods/harmonization/areas/pbpk-models.pdf (2010).
27. Willmann, S., Edginton, A.N., Kleine-Besten, M., Jantratid, E., Thelen, K. & Dressman, J.B. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J. Pharm. Pharmacol. 61, 891-899 (2009).
28. Parrott, N. et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 50, 613-623 (2011).
29. Jamei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009).
30. Willmann, S. et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431 (2007).
31. Price, P.S. et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33, 469-503 (2003).
32. Yu, L.X., Crison, J.R. & Amidon, G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140, 111-118 (1996).
33. Huang, W., Lee, S.L. & Yu, L.X. Mechanistic approaches to predicting oral drug absorption. AAPS J. 11, 217-224 (2009).
34. Kostewicz, E.S. et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci. 57, 300-321 (2014).
35. ICRP. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Vol. ICRP Publication 89. (Elsevier Science, Amsterdam, The Netherlands, 2002).
36. McNamara, P.J. & Alcorn, J. Protein binding predictions in infants. AAPS PharmSci 4, E4 (2002).
37. Alcorn, J. & McNamara, P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin. Pharmacokinet. 41, 1077-1094 (2002).
38. Edginton, A.N., Schmitt, W., Voith, B. & Willmann, S. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45, 683-704 (2006).
39. Rhodin, M.M. et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67-76 (2009).
40. Hayton, W.L. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2, E3 (2000).
41. Jonsson, F., Bois, F. & Johanson, G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 59, 209-218 (2001).
42. Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238-1257 (2006).